C4 Therapeutics, Inc. short interest in 2023
In 2023, C4 Therapeutics, Inc.'s disclosed short interest ran from 7.30% of shares outstanding on 13 Jan 2023 to 9.21% on 29 Dec 2023, a change of +1.91 percentage points. The year's high was 9.21% on 29 Dec 2023 and its low 3.72% on 13 Oct 2023, averaging 5.49% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.28 days on 31 Jan 2023. Full history: C4 Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 7.30% (13 Jan 2023)
- End of year
- 9.21% (29 Dec 2023)
- Change
- +1.91 pp
- High
- 9.21% (29 Dec 2023)
- Low
- 3.72% (13 Oct 2023)
- Average
- 5.49%
- Highest days to cover
- 10.28 (31 Jan 2023)
- SEC filings marked
- 8
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 7.30% | 8.24 | |
| 31 Jan 2023 | 7.53% | 10.28 | |
| 15 Feb 2023 | 6.57% | 4.07 | |
| 28 Feb 2023 | 6.64% | 5.29 | 10-K filed, results (8-K) |
| 15 Mar 2023 | 5.97% | 5.89 | |
| 31 Mar 2023 | 5.37% | 3.93 | |
| 14 Apr 2023 | 5.78% | 5.07 | |
| 28 Apr 2023 | 5.88% | 9.32 | |
| 15 May 2023 | 5.91% | 4.68 | 10-Q filed, results (8-K) |
| 31 May 2023 | 6.62% | 4.82 | |
| 15 Jun 2023 | 6.81% | 5.34 | |
| 30 Jun 2023 | 5.02% | 2.12 | |
| 14 Jul 2023 | 4.57% | 1.00 | |
| 31 Jul 2023 | 4.29% | 4.56 | |
| 15 Aug 2023 | 3.86% | 5.02 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 4.24% | 7.77 | |
| 15 Sep 2023 | 4.84% | 6.42 | |
| 29 Sep 2023 | 4.60% | 3.46 | |
| 13 Oct 2023 | 3.72% | 4.70 | |
| 31 Oct 2023 | 3.87% | 2.55 | |
| 15 Nov 2023 | 3.97% | 4.26 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 3.81% | 8.63 | |
| 29 Dec 2023 | 9.21% | 1.00 |
See also: C4 Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.